This presentation will explore the many implications to testing for RAS in a Pan- tumor setting. Discussion will include the expanding role of RAS in tumor profiling, the potential for actionability of RAS, RAS prevalence, the importance of understanding the urgency with which to get a RAS Status where this was once seen as "untreatable" as well how the pathologist can act to make a difference.
